Zydus Lifesciences has received a Warning Letter from the USFDA for its Baddi manufacturing facility, according to a BSE filing. The company stated it would engage with the regulator to address concerns raised.
Company Update Receipt of Warning Letter from USFDA for Baddi facility Receipt of Warning Letter from USFDA for Baddi facility Receipt of Warning Letter from USFDA for Baddi facility
Company Update Receipt of Warning Letter from USFDA for Baddi facility Receipt of Warning Letter from USFDA for Baddi facility Receipt of Warning Letter from USFDA for Baddi facility
Zydus Lifesciences Limited has filed a buyback notice with the NSE, joining a list of pharmaceutical companies returning capital to shareholders through share repurchase programs.
Buyback Zydus Lifesciences Limited has informed the Exchange about Buyback Zydus Lifesciences Limited has informed the Exchange about Buyback Zydus Lifesciences Limited has informed the Exchange about Buyback
Zydus Lifesciences Limited has informed the NSE about initiating a share buyback program. Detailed parameters regarding pricing, size, and timeline are expected in the official filing.
Zydus Lifesciences Limited (NSE: ZYDUSLIFE) has notified the exchanges about a share buyback program. The announcement signals the pharma major's intent to return capital to shareholders.
Zydus Lifesciences Limited has notified the exchange about a share buyback, marking another step in the pharmaceutical company's capital optimization efforts.
Buyback Zydus Lifesciences Limited has informed the Exchange about Buyback Zydus Lifesciences Limited has informed the Exchange about Buyback Zydus Lifesciences Limited has informed the Exchange about Buyback
Company Update Zydus Therapeutics'' New Drug Application (NDA) for Saroglitazar to treat Primary Biliary Cholangitis (PBC) granted Priority Review by the US FDA. Zydus Therapeutics'' New Drug Application (NDA) for Saroglitazar to treat Primary Biliary Cholangitis (PBC) granted Priority Review by the US FDA. Zydus Therapeutics'' New Drug Application (NDA) for Saroglitazar to treat Primary Biliary Cholangitis (PBC) granted Priority Review by the US FDA.
Press Release Zydus Lifesciences Limited has informed the Exchange regarding a press release dated May 28, 2026, titled "Zydus Therapeutics New Drug Application (NDA) for Saroglitazar to treat Primary Biliary Cholangitis (PBC) granted Priority Review by the US FDA". Zydus Lifesciences Limited has informed the Exchange regarding a press release dated May 28, 2026, titled "Zydus Therapeutics New Drug Application (NDA) for Saroglitazar to treat Primary Biliary Cholangitis (PBC) granted Priority
Zydus VTEC Limited, the wholly owned subsidiary of Zydus Lifesciences, has received a Demand Order-In-Original from the Deputy Commissioner of CGST & Central Excise based in Ahmedabad North Commissionerate.
NSE & BSE filings, earnings, insider trades, and smart volume alerts — on WhatsApp or Telegram. No separate app to install.